The divergence between the negative TTM P/E and the positive forward P/E indicates that the market expects a normalization of earnings, likely assuming that non-recurring impairment charges will subside. However, the EV/EBITDA multiple of 16.09 remains elevated relative to peers like T. Rowe Price, suggesting that the market is cautious about the firm's underlying operational efficiency and debt-adjusted valuation.

The persistent weakness in ROIC relative to peers like T. Rowe Price suggests that Invesco's capital allocation strategy has not yet generated sufficient returns to justify the massive intangible asset base on its balance sheet. Investors should monitor whether future management decisions prioritize organic growth over further M&A to improve these returns.

The lack of meaningful improvement in asset turnover suggests that the firm's growth is largely tethered to market beta rather than operational productivity. The variability in DSO, which has fluctuated between 42 and 67 days, further implies that the firm's cash conversion cycle is susceptible to timing mismatches in fee collection from institutional and retail intermediaries.

The interest coverage ratio, which has seen extreme swings including negative values during periods of impairment, suggests that debt service is becoming less comfortable than in prior years. This leverage profile appears more aggressive than peers like T. Rowe Price, potentially exposing shareholders to higher risk if market-driven AUM declines persist.